

**GLOBAL CARE CAPITAL INC.**  
**(FORMERLY RESINCO CAPITAL PARTNERS INC.)**  
**CONDENSED INTERIM FINANCIAL STATEMENTS**  
**FOR THE THREE MONTHS ENDED**  
**MARCH 31, 2021 AND 2020**  
**Unaudited – Prepared by Management**  
(Expressed in Canadian Dollars)

---

**NOTICE OF NO AUDITOR REVIEW  
OF CONDENSED INTERIM FINANCIAL STATEMENTS**

Under National Instrument 51-102, Continuous Disclosure Requirement, if an auditor has not performed a review of the condensed interim financial statements, they must be accompanied by a notice indicating that the unaudited condensed interim financial statements have not been reviewed by an auditor.

The accompanying unaudited condensed interim financial statements of Global Care Capital Partners Inc. (formerly Resinco Capital Partners Inc.) have been prepared by and are the responsibility of management. These condensed interim financial statements as at March 31, 2021 and for the three months then ended, have not been reviewed or audited by the Company's independent auditors in accordance with standards established by the Chartered Professional Accountants of Canada.

---

**GLOBAL CARE CAPITAL INC. (FORMERLY RESINCO CAPITAL PARTNERS INC.)**  
**CONDENSED INTERIM STATEMENTS OF FINANCIAL POSITION**  
**(UNAUDITED - EXPRESSED IN CANADIAN DOLLARS)**

		<b>March 31,</b>	December 31,
		<b>2021</b>	2020
	<b>Notes</b>	<b>\$</b>	(Audited) <b>\$</b>
<b>ASSETS</b>			
Current Assets			
Cash and cash equivalents		<b>505,187</b>	321,608
Prepays	<b>4</b>	<b>713,779</b>	-
Investments	<b>5</b>	<b>372,018</b>	223,670
		<b>1,590,984</b>	545,278
Non-Current Assets			
Investments	<b>5</b>	<b>11,666,669</b>	166,669
<b>Total assets</b>		<b>13,257,653</b>	711,947
<b>LIABILITIES</b>			
Current Liabilities			
Accounts payable and accrued liabilities	<b>6, 9</b>	<b>499,835</b>	371,356
Loan payable	<b>7</b>	<b>536,968</b>	-
Contingent consideration liability	<b>5, 8</b>	-	1,700,000
<b>Total liabilities</b>		<b>1,036,803</b>	2,071,356
<b>SHAREHOLDERS' EQUITY (DEFICIENCY)</b>			
Share capital	<b>8</b>	<b>110,649,068</b>	96,909,265
Share-based payments reserve	<b>8</b>	<b>24,131,908</b>	23,714,464
Accumulated deficit		<b>(122,560,126)</b>	(121,983,138)
<b>Total shareholders' equity (deficiency)</b>		<b>12,220,850</b>	(1,359,409)
<b>Total liabilities and shareholders' equity (deficiency)</b>		<b>13,257,653</b>	711,947

Nature of operations and going concern (Note 1)

Subsequent events (Note 12)

These condensed interim financial statements were approved for issue by the Board of Directors of the Company on May 28, 2021.

They are signed on the Company's behalf by:

"Alexander Somjen" Director "Maciej Lis" Director

The accompanying notes are integral to these condensed interim financial statements

**GLOBAL CARE CAPITAL INC. (FORMERLY RESINCO CAPITAL PARTNERS INC.)**  
**CONDENSED INTERIM STATEMENTS OF NET LOSS AND COMPREHENSIVE LOSS**  
**(UNAUDITED - EXPRESSED IN CANADIAN DOLLARS)**

		<b>Three month period ended</b>	
	<b>Notes</b>	<b>March 31, 2021</b>	<b>March 31, 2020</b>
		<b>\$</b>	<b>\$</b>
<b>Investment income</b>			
Net realized loss on disposal of investments		-	8,604
Net change in unrealized gains on investments	<b>5</b>	<b>148,347</b>	24,817
		<b>148,347</b>	33,421
Interest income		-	2,244
<b>Net investment income</b>		<b>188,848</b>	35,665
<b>Expenses</b>			
Advertising and promotion		(169,145)	-
Consulting fees	<b>9</b>	(88,540)	(68,600)
Office and miscellaneous		(2,236)	(3,293)
Professional fees		(41,486)	(16,969)
Regulatory and transfer agent fees		(6,682)	(5,179)
Share-based compensation	<b>8</b>	(417,247)	-
		<b>(725,336)</b>	(94,041)
Net loss and comprehensive loss for the period		<b>(576,989)</b>	(58,376)
Net loss and comprehensive loss per share, basic and diluted		<b>(0.01)</b>	(0.01)
Weighted average number of shares outstanding, basic and diluted		<b>105,293,235</b>	4,893,235

The accompanying notes are integral to these condensed interim financial statements

**GLOBAL CARE CAPITAL INC. (FORMERLY RESINCO CAPITAL PARTNERS INC.)**  
**CONDENSED INTERIM STATEMENTS OF CASH FLOWS**  
**(UNAUDITED - EXPRESSED IN CANADIAN DOLLARS)**

	<b>Three month period ended</b>	
	<b>March 31, 2021</b>	<b>March 31, 2020</b>
	<b>\$</b>	<b>\$</b>
<b>Operating activities</b>		
Net loss and comprehensive loss for the period	(576,989)	(57,565)
Items not affecting cash:		
Accrued interest on loan payable	-	(2,244)
Realized loss on sale of investments	(148,347)	(8,604)
Fair value change in investments	-	(24,817)
Share-based compensation	417,247	-
	(308,089)	(93,230)
Changes in non-cash working capital items:		
Prepaid expenses	(713,779)	-
Accounts payable and accrued liabilities	165,612	23,196
Proceeds from sale of investments	-	29,581
<b>Net cash used in operating activities</b>	<b>(856,256)</b>	<b>(40,453)</b>
<b>Financing activities</b>		
Proceeds from loan payable	499,835	50,000
Exercise of warrants	540,000	-
<b>Net cash provided by financing activities</b>	<b>1,039,835</b>	<b>50,000</b>
<b>Change in cash</b>	<b>183,579</b>	<b>9,547</b>
<b>Cash and cash equivalents, beginning</b>	<b>321,608</b>	<b>14,498</b>
<b>Cash and cash equivalents, ending</b>	<b>505,187</b>	<b>24,045</b>
<b>Non-cash financing activities</b>		
Shares issued for acquisition of ASIC	\$11,500,000	\$ -
Share issued to settle consideration payable	\$ 1,700,000	\$ -
Fair value of finders' warrants issued	\$ 24,591	\$ -
Fair value of finders' warrants exercise	\$ 24,394	\$ -

The accompanying notes are integral to these condensed interim financial statements

**GLOBAL CARE CAPITAL INC. (FORMERLY RESINCO CAPITAL PARTNERS INC.)**  
**STATEMENTS OF CHANGES IN EQUITY (DEFICIENCY)**  
**FOR THE THREE MONTHS ENDED MARCH 31, 2021 AND 2020**  
**(UNAUDITED - EXPRESSED IN CANADIAN DOLLARS)**

	Number of Shares		Share Capital		Share-based payments reserve		Accumulated deficit		Total Shareholders' Equity
Balance, December 31, 2019	4,893,240	\$	53,353,405	\$	16,849,827	\$	(68,602,875)	\$	1,600,357
Loss and comprehensive loss for the period	-		-		-		(58,376)		(58,376)
Balance, March 31, 2020	4,893,240	\$	53,353,405	\$	16,849,827	\$	(68,661,251)	\$	1,541,981
Balance, December 31, 2020	105,543,240	\$	96,909,265	\$	23,714,464	\$	(121,983,138)	\$	(1,359,409)
Share issued to settle consideration payable	20,000,000		1,700,000		-		-		1,700,000
Warrants issued as finder fees	-		(24,591)		24,591		-		-
Shares issued for acquisition of ASIC	100,000,000		11,500,000		-		-		11,500,000
Warrants exercise	10,075,000		527,500		-		-		515,000
Finders' Warrants exercise	250,000		36,894		(24,394)		-		25,000
Share based compensation	-		-		417,247		-		417,247
Loss and comprehensive loss for the period	-		-		-		(576,989)		(576,989)
<b>Balance, March 31, 2021</b>	<b>235,868,240</b>	<b>\$</b>	<b>110,649,068</b>	<b>\$</b>	<b>24,131,908</b>	<b>\$</b>	<b>(122,560,126)</b>	<b>\$</b>	<b>12,220,850</b>

The accompanying notes are integral to these condensed interim financial statements

**GLOBAL CARE CAPITAL INC. (FORMERLY RESINCO CAPITAL PARTNERS INC.)**  
**NOTES TO THE CONDENSED INTERIM FINANCIAL STATEMENTS**  
**FOR THE THREE MONTH PERIOD ENDED MARCH 31, 2021 AND 2020**  
**(UNAUDITED - EXPRESSED IN CANADIAN DOLLARS)**

---

**1. NATURE OF OPERATIONS AND GOING CONCERN**

---

Global Care Capital Inc. (formerly Resinco Capital Partners Inc.) (“Global Care Capital” or the “Company”) was incorporated under the laws of British Columbia on May 25, 2004. On April 13, 2020, the Company changed its name from Resinco Capital Partners Inc. to Global Care Capital Inc. The Company’s shares are listed for trading on the Canadian Securities Exchange (“CSE”) under the ticker symbol “HLTH”, the Frankfurt Stock Exchange under the symbol L6V1.F and in the US on the OTC market, under the symbol RSCZF. The registered office of the Company is Suite 810 – 789 West Pender Street, Vancouver, British Columbia, Canada, V6C 1H2.

Global Care Capital is a global investment company which specializes in providing early-stage financing to private and public companies in the medical marijuana, pharmaceutical, technology, and mining sectors. The Company engages in new, early-stage investment opportunities in previously underdeveloped assets and obtaining significant positions in early-stage investment opportunities that adequately reflect the risk profile.

These condensed interim financial statements have been prepared on a going concern basis, which assumes that the Company will be able to realize its assets and discharge its liabilities in the normal course of business. As at March 31, 2021, the Company has a working capital (deficit) of \$554,181 (December 31, 2020 - \$(1,526,076)) and accumulated deficit of \$122,560,126 (December 31, 2020 - \$121,983,138). These factors indicate the existence of a material uncertainty that may raise significant doubt about the Company’s ability to continue as a going concern. The continued operations of the Company are dependent on its ability to generate cash flows from additional equity financing and/or through the sales of investments. These condensed interim financial statements do not reflect any adjustments that may be necessary if the Company is unable to continue as a going concern, in which case such adjustments could be material.

In March 2020, the World Health Organization declared coronavirus COVID-19 a global pandemic. This contagious disease outbreak, which has continued to spread, and any related adverse public health developments, has adversely affected workforces, economies, and financial markets globally, potentially leading to an economic downturn. The impact on the Company is not currently determinable but management continues to monitor the situation.

**2. BASIS OF PRESENTATION AND STATEMENT OF COMPLIANCE**

---

**Statement of compliance**

These condensed interim financial statements have been prepared in accordance with International Accounting Standard 34 Interim Financial Reporting (“IAS 34”) as issued by the International Accounting Standards Board (“IASB”). The policies applied in these condensed interim financial statements are based on International Financial Reporting Standards (“IFRS”) issued and outstanding as at the date the Board of Directors approved these condensed interim financial statements for issue.

These condensed interim financial statements do not include all of the information and disclosures required by IFRS for annual financial statements and therefore should be read in conjunction with the Company’s annual financial statements for the year ended December 31, 2020.

**GLOBAL CARE CAPITAL INC. (FORMERLY RESINCO CAPITAL PARTNERS INC.)**  
**NOTES TO THE CONDENSED INTERIM FINANCIAL STATEMENTS**  
**FOR THE THREE MONTH PERIOD ENDED MARCH 31, 2021 AND 2020**  
**(UNAUDITED - EXPRESSED IN CANADIAN DOLLARS)**

---

**2. BASIS OF PRESENTATION AND STATEMENT OF COMPLIANCE (continued)**

---

**Basis of presentation**

These condensed interim financial statements have been prepared on the historical cost basis except for certain financial instruments which are measured at fair value. In addition, these condensed interim financial statements have been prepared using the accrual basis of accounting, except for cash flow information.

On March 13, 2020, the Company completed a share consolidation of its share capital on the basis of twenty-five (25) existing common shares for one (1) new common share. As a result of the share consolidation, the 122,331,000 common shares issued and outstanding were consolidated to 4,893,240 common shares. All common shares and per share amounts have been restated to give effect to the share consolidation (Note 8).

For the period ended March 31, 2020, the Company has changed the presentation of \$29,581 of cash inflows relating to proceeds from the sale of investments from investing activities to operating activities in the statement of cash flows to reflect the economic substance of transactions.

**Functional and presentation currency**

These condensed interim financial statements are presented in Canadian Dollars, which is the Company's functional and presentation currency.

**Use of estimates and judgments**

The preparation of the condensed interim financial statements requires management to make certain estimates, judgments and assumptions that affect the reported amounts of assets and liabilities at the date of the condensed interim financial statements and reported amounts of expenses during the reporting period. Actual outcomes could differ from these estimates. The condensed interim financial statements include estimates which, by their nature, are uncertain. The impact of such estimates are pervasive throughout the condensed interim financial statements, and may require accounting adjustments based on future occurrences. Revisions to accounting estimates are recognized in the period in which the estimate is revised and future periods if the revision affects both current and future periods. These estimates are based on historical experience, current and future economic conditions and other factors, including expectations of future events that are believed to be reasonable under the circumstances.

Information about critical judgments in applying accounting policies and sources of estimation uncertainty that have the most significant risk of causing material adjustment to the carrying amounts of assets and liabilities recognized in the condensed interim financial statements within the next financial year are the same as those that applied to the Company's 2020 audited financial statements.

**3. SIGNIFICANT ACCOUNTING POLICIES**

---

The condensed interim financial statements have been prepared using accounting policies consistent with those used in the Company's 2020 audited financial statements. These condensed interim financial statements should be read in conjunction with the audited financial statements of the Company as at and for the year ended December 31, 2020.

**4. PREPAIDS**

---

During the period ended March 31, 2021, the company paid a CDN\$713,779 (EUR \$460,000) deposit in connection with a Streaming Agreement between the Company and ASIC Power Company ("ASIC").



**GLOBAL CARE CAPITAL INC. (FORMERLY RESINCO CAPITAL PARTNERS INC.)**  
**NOTES TO THE CONDENSED INTERIM FINANCIAL STATEMENTS**  
**FOR THE THREE MONTH PERIOD ENDED MARCH 31, 2021 AND 2020**  
**(UNAUDITED - EXPRESSED IN CANADIAN DOLLARS)**

**5. INVESTMENTS**

At March 31, 2021, the Company held the following investments:

Investee	Number of Shares	Cost \$	Fair Value \$
<b>Public Companies</b>			
Metaverse Capital Corp.	5,058,583	101,172	-
180 Life Sciences Corp.	44,240	272,000	365,001
Total of 2 other public company investments, each valued under \$15,000		40,598	7,017
		988,881	372,018
<b>Private Companies</b>			
ASIC Power Company	10,000,000	11,500,000	11,500,000
Pembroke Copper Corp.	320,000	452,000	1
Vancity Green List Inc.	100	1,200,000	-
High Standard Health Care Ltd.	27,000,000	6,885,000	-
ViralClear Rapid Test Corp.	24,000,000	30,554,645	166,668
Healthview Technologies Inc.	20,000,000	3,250,000	-
360 Life Sciences Corp.	800,000	10,750,000	-
		64,591,645	11,666,669
		65,580,526	12,038,687

At December 31, 2020, the Company held the following investments:

Investee	Number of Shares	Cost \$	Fair Value \$
<b>Public Companies</b>			
Global Gaming Technologies Corp.	720,000	575,111	63,253
Metaverse Capital Corp.	5,058,583	101,172	-
180 Life Sciences Corp.	44,240	272,000	153,771
Total of 2 other public company investments, each valued under \$15,000		40,598	6,646
		988,881	223,670
<b>Private Companies</b>			
Pembroke Copper Corp.	320,000	452,000	1
Vancity Green List Inc.	100	1,200,000	-
High Standard Health Care Ltd.	27,000,000	6,885,000	-
ViralClear Rapid Test Corp.	24,000,000	30,554,645	166,668
Healthview Technologies Inc.	20,000,000	3,250,000	-
360 Life Sciences Corp.	800,000	10,750,000	-
		53,091,645	166,669
		54,080,526	390,339

**GLOBAL CARE CAPITAL INC. (FORMERLY RESINCO CAPITAL PARTNERS INC.)**  
**NOTES TO THE CONDENSED INTERIM FINANCIAL STATEMENTS**  
**FOR THE THREE MONTH PERIOD ENDED MARCH 31, 2021 AND 2020**  
**(UNAUDITED - EXPRESSED IN CANADIAN DOLLARS)**

---

**5. INVESTMENTS (continued)**

---

*Healthview Technologies Inc.*

On September 14, 2020, the Company acquired all of the issued and outstanding securities in the capital of Healthview Technologies Inc. ("Healthview") in exchange for 20,000,000 common shares of the Company with an estimated fair value of \$1,300,000 and 20,000,000 contingently issuable shares with an estimated fair value of \$1,950,000. Healthview provides wellness support and mental health solutions and services to both employers and employees. As at December 31, 2020, the contingent consideration liability was re-measured to \$1,700,000. As at March 31, 2021, the estimated fair value of Healthview was \$Nil (December 31, 2020 - \$Nil).

During the period ended March 31, 2021, Healthview achieved its two earn-out milestones by onboarding its first customers across the retail, hospitality, medical, finance and transportation industries to offer Mental Health Services and by generating revenue. As a result, the Company issued 20,000,000 common shares (the "Earn-Out Shares") with a fair value of \$1,700,000. The Earn-Out Shares will not be subject to any hold period under applicable securities laws.

*360 Life Sciences Corp.*

On August 4, 2020, the Company sold all of the issued and outstanding shares of its wholly-owned subsidiary ReFormation Pharmaceuticals Corp. ("ReFormation") to 360 Life Sciences Corp. (the "Purchaser") pursuant to the share purchase agreement between Global Care and the Purchaser signed on June 24, 2020. The Purchaser acquired all the issued and outstanding shares of ReFormation in exchange for 800,000 common shares of the Purchaser with an estimated fair value of \$Nil. As at March 31, 2021, the estimated fair value of 360 Life Sciences Corp. was \$Nil.

*High Standard Health Care Ltd.*

On June 5, 2020, the Company acquired 70% of High Standard Health Care Ltd. ("HSHC") in exchange for 27,000,000 of the Company's common shares with an estimated fair value of \$6,885,000. HSHC specializes in procuring personal protective equipment ("PPE") including but not limited to respiratory masks, hand sanitizer, gowns, infrared thermometers and face shields and has been active in procurement during COVID-19 for hospitals, municipalities, long-term care facilities, fire departments and police departments.

Under the agreement, the Company will pay \$5,000,000 cash or issue common shares ("Performance Shares") at the discretion of the Company at the time a Milestone Target is met for every \$14,300,000 in gross revenue generated by HSHC effective upon HSHC reaching \$21,430,000 in revenue ("Milestone Targets") up to a maximum of \$286,000,000 in gross revenue or 20 Milestone Targets on or before May 31, 2025 for total value of up to \$100,000,000 if all Milestone Targets are achieved. The Company may issue up to 26,500,000 Payment Shares in satisfaction of met Milestone Targets. The Company recognized a contingent consideration liability with an estimated fair value of \$500,000. As at December 31, 2020, the contingent consideration liability was re-measured to \$nil. As at December 31, 2020, management determined that the investment in HSHC was not expected to be recoverable and reduced the estimated fair value of the investment to \$Nil.

*ViralClear Rapid Test Corp.*

On April 17, 2020, the Company acquired 100% interest in ViralClear Rapid Test Corp. ("ViralClear") in exchange for 24,000,000 of the Company's common shares with an estimated fair value of \$30,554,645. The Company paid finders' fees to an arm's-length party of 2,400,000 common shares with an estimated fair value of \$3,055,465. As at December 31, 2020, the investment was re-measured to its estimated fair value of \$166,668 using a net asset approach. As at March 31, 2021, the estimated fair value of ViralClear is \$166,668.

**GLOBAL CARE CAPITAL INC. (FORMERLY RESINCO CAPITAL PARTNERS INC.)**  
**NOTES TO THE CONDENSED INTERIM FINANCIAL STATEMENTS**  
**FOR THE THREE MONTH PERIOD ENDED MARCH 31, 2021 AND 2020**  
**(UNAUDITED - EXPRESSED IN CANADIAN DOLLARS)**

---

**5. INVESTMENTS (continued)**

---

*180 Life Sciences Corp.*

On November 6, 2020, the Company acquired 100% of 180 Life Sciences Corp (“180”) by exchanging 263 CannaBioRX shares the Company held for 44,240 180 Life Sciences Corp shares at a fair value of \$153,771. As at March 31, 2021, the fair value of 180 is \$365,001 (December 31, 2020 - \$153,771). The Company recorded an unrealized gain on investments of \$211,230 for the period ended March 31, 2021.

*Vancity Green List Inc.*

On December 28, 2018, the Company acquired 100% of Vancity Green List Inc. (“Vancity”) by way of a three-cornered amalgamation. Vancity is a leading website application that connects personal use cannabis growers and local dispensaries. In consideration, the Company issued 600,000 common shares with a fair value of \$1,200,000. As at March 31, 2021, the fair value of Vancity was \$Nil. (December 31, 2020 - \$Nil)

*ASIC Power Company*

On January 28, 2021, the Company acquired all of the issued and outstanding securities in the capital of ASIC in exchange for 100,000,000 common shares of the Company with a fair value of \$11,500,000 issued to ASIC shareholders. ASIC is a cryptocurrency company combining state of the art ASIC chips with royalty streaming contracts.

**6. ACCOUNTS PAYABLE AND ACCRUED LIABILITIES**

---

The Company’s accounts payable and accrued liabilities are as follows:

	March 31, 2021	December 31, 2020
	\$	\$
Trade payables	113,860	97,206
Accrued liabilities	385,975	274,150
Total	499,835	371,356

**7. LOAN PAYABLE**

---

During the period ended March 31, 2021, the Company received unsecured loan proceeds of \$499,835 (December 31, 2020 - \$Nil) from arms-length parties. These loans are unsecured, non-interest bearing and due on demand.

**GLOBAL CARE CAPITAL INC. (FORMERLY RESINCO CAPITAL PARTNERS INC.)**  
**NOTES TO THE CONDENSED INTERIM FINANCIAL STATEMENTS**  
**FOR THE THREE MONTH PERIOD ENDED MARCH 31, 2021 AND 2020**  
**(UNAUDITED - EXPRESSED IN CANADIAN DOLLARS)**

---

**8. SHARE CAPITAL**

---

**a) Authorized share capital**

At March 31, 2021, the authorized share capital comprised an unlimited number of common shares without par value.

**b) Issued share capital**

At March 31, 2021, the Company had 235,856,240 (December 31, 2020 – 105,543,240) common shares issued and outstanding.

*During the period ended March 31, 2021:*

On January 28, 2021, the Company issued 100,000,000 common shares of the Company to ASIC shareholders. On completion of the acquisition of all of the issued and outstanding securities in the capital of ASIC with a fair value of \$11,500,000 (Note 5).

On February 2, 2021, the Company issued 10,000,000 common shares to Healthview with a fair value of \$900,000 in connection in achieving the first earn-out milestone whereby they onboarded their first customers across the retail, hospitality, medical, finance and transportation industries to offer Mental Health Services (Note 5).

On March 4, 2021, the Company issued 10,000,000 common shares to Healthview with a fair value of \$800,000 in connection with achieving its second and final of two earn-out milestones by generating revenue (Note 5).

During the period ended March 31, 2021, the Company issued 10,075,000 common shares for total proceeds of \$515,000 pursuant to warrants exercised.

During the period ended March 31, 2021, the Company issued 250,000 common shares for total proceeds of \$25,000 pursuant to the exercise of finder's warrants exercised. In addition, \$24,394 representing the fair value of the finders warrants was re-allocated from share-based payments reserves to share capital.

*During the year ended December 31, 2020:*

During the year ended December 31, 2020, the Company issued 25,000,000 common shares for gross proceeds of \$2,500,000 pursuant to private placements and issued 250,000 common shares for gross proceeds of \$125,000 pursuant to stock options exercised.

On September 15, 2020, the Company issued 20,000,000 common shares, with a fair value of \$1,300,000 to acquire 100% of Healthview Technologies Inc. The Company also issued 2,000,000 common shares for a fair value of \$130,000 for finder's fee pursuant to the acquisition.

On June 5, 2020, the Company issued 27,000,000 common shares, with a fair value of \$6,885,000 to acquire 70% of HSHC.

On April 17, 2020, the Company issued 24,000,000 of the Company's common shares with a fair value of \$30,000,000 to acquire 100% interest in ViralClear. The Company has also issued an aggregate 2,400,000 common shares with a fair value of \$3,000,000 to an arm's-length party as payment of finder's fees.

**GLOBAL CARE CAPITAL INC. (FORMERLY RESINCO CAPITAL PARTNERS INC.)**  
**NOTES TO THE CONDENSED INTERIM FINANCIAL STATEMENTS**  
**FOR THE THREE MONTH PERIOD ENDED MARCH 31, 2021 AND 2020**  
**(UNAUDITED - EXPRESSED IN CANADIAN DOLLARS)**

**8. SHARE CAPITAL (continued)**

**b) Issued share capital (continued)**

On April 9, 2020, the Company closed a non-brokered private placement by issuance of 25,000,000 common shares and 12,500,000 warrants of each whole warrant is convertible for one common share, for gross proceeds of \$2,450,000 and to settle outstanding debt of \$50,000. The Company paid \$194,425 in finders' fee and issued 1,944,250 finder warrants with a fair value of \$189,715, calculated using the Black-Scholes pricing model with the following assumptions: term of 2 years; expected volatility of 318%; risk-free rate of 0.40%; and expected dividends of zero. The Company re-allocated \$189,715 from share capital to share-based payments reserve.

**c) Stock options – Directors, officers, employees and consultants**

The Board of Directors of the Company may from time-to-time grant to directors, officers, employees and consultants of the Company, non-transferable options to purchase common shares, provided that the number of common shares reserved for issuance will not exceed 10% of the issued and outstanding common shares, exercisable for a period of up to five years from the date of grant. The Company's stock option plan requires that options vest 20% immediately, with 20% vesting every nine months thereafter; however, the Board may change such provisions at its discretion or as required on a grant-by-grant basis.

The continuity for stock options granted to directors, officers, employees and consultants of the Company for the period ended March 31, 2021 is as follows:

<b>Grant Date</b>	<b>Expiry date</b>	<b>Number of options</b>	<b>Exercise price</b>
June 22, 2018	June 22, 2023	156,560	\$ 5.500
April 9, 2020	April 9, 2022	2,299,463	0.660
April 17, 2020	April 15, 2022	500,000	0.200
April 17, 2020	April 15, 2022	2,150,000	0.500
June 5, 2020	June 5, 2022	1,000,000	0.290
February 4, 2021	February 4, 2026	3,650,000	0.115
<b>Balance at March 31, 2021</b>		<b>9,756,023</b>	<b>\$ 0.440</b>

	<b>Number of options</b>	<b>Weighted average exercise price</b>
<b>Balance at December 31, 2020</b>	<b>6,106,023</b>	<b>\$ 0.630</b>
Options granted	3,650,000	0.115
Options exercised	-	-
Options cancelled and expired	-	-
<b>Balance at March 31, 2021</b>	<b>9,756,023</b>	<b>\$ 0.44</b>

The continuity for stock options granted to directors, officers, employees and consultants of the Company for the year ended December, 2020 is as follows:

	<b>Number of options</b>	<b>Weighted average exercise price</b>
<b>Balance at December 31, 2019</b>	<b>164,560</b>	<b>\$ 5.50</b>
Options granted	6,199,463	0.50
Options exercised	(250,000)	0.50
Options cancelled and expired	(8,000)	5.50
<b>Balance at December 31, 2020</b>	<b>6,106,023</b>	<b>\$ 0.63</b>

**GLOBAL CARE CAPITAL INC. (FORMERLY RESINCO CAPITAL PARTNERS INC.)**  
**NOTES TO THE CONDENSED INTERIM FINANCIAL STATEMENTS**  
**FOR THE THREE MONTH PERIOD ENDED MARCH 31, 2021 AND 2020**  
**(UNAUDITED - EXPRESSED IN CANADIAN DOLLARS)**

**8. SHARE CAPITAL (continued)**

**c) Stock options – Directors, officers, employees and consultants (continued)**

On February 4, 2021, the Company granted 3,650,000 stock options with an exercise price of \$0.115 per share expiring on February 4, 2026. The fair value of the stock options was estimated to be \$417,247 using the Black-Scholes pricing model with the following assumptions: term - 5 years; expected volatility – 267.40%; risk-free rate - 0.32%; and expected dividends - zero.

**d) Finders' warrants**

The continuity for finders' warrants for the period ended March 31, 2021 is as follows:

	Number of warrants	Weighted average exercise price
<b>Balance at December 31, 2020</b>	1,944,250	\$ 0.10
Warrants granted	125,000	0.20
Warrants exercised	(250,000)	0.10
<b>Balance at March 31, 2021</b>	1,819,250	\$ 0.22

The continuity for finders' warrants for the year ended December 31, 2020 is as follows:

	Number of warrants	Weighted average exercise price
<b>Balance at December 31, 2019</b>	-	\$ -
Warrants granted	1,944,250	0.10
<b>Balance at December 31, 2020</b>	1,944,250	\$ 0.10

On February 21, 2021, the Company issued 125,000 finder's warrants with an exercise price of \$0.20 per share expiring on April 9, 2022 in connection with a private placement completed on April 9, 2020. The 125,000 finder's warrants remained exercisable on March 31, 2021. The fair value of the finder's warrants was estimated to be \$24,591 using the Black-Scholes pricing model with the following assumptions: term – 1.13 years; expected volatility – 308.48%; risk-free rate - 0.41%; and expected dividends - zero.

**e) Warrants**

The continuity for warrants for the period ended March 31, 2021 is as follows:

	Number of warrants	Weighted average exercise price
<b>Balance at December 31, 2020</b>	25,500,000	\$ 0.16
Warrants exercised	(10,075,000)	0.16
<b>Balance at March 31, 2021</b>	15,425,000	\$ 0.16

The continuity for warrants for the year ended December 31, 2020 is as follows:

	Number of warrants	Weighted average exercise price
<b>Balance at December 31, 2019</b>	-	\$ -
Warrants granted	25,500,000	0.16
<b>Balance at December 31, 2020</b>	25,500,000	\$ 0.16

**GLOBAL CARE CAPITAL INC. (FORMERLY RESINCO CAPITAL PARTNERS INC.)**  
**NOTES TO THE CONDENSED INTERIM FINANCIAL STATEMENTS**  
**FOR THE THREE MONTH PERIOD ENDED MARCH 31, 2021 AND 2020**  
**(UNAUDITED - EXPRESSED IN CANADIAN DOLLARS)**

**9. RELATED PARTY TRANSACTIONS AND BALANCES**

The following directors and/or senior officers transacted with the Company in the reporting year. The terms and conditions of the transactions with key management personnel and their related parties were no more favourable than those available, or which might reasonably be expected to be available, on similar transactions to non-key management personnel related entities on an arm's length basis. The aggregate value of transactions relating to key management personnel were as follows:

	<b>March 31, 2021</b>	<b>March 31, 2020</b>
	\$	\$
Consulting fees paid to a company controlled by the CEO	\$ 33,900	\$ 50,850
Consulting fees paid to the CFO (should be \$1,500)	1,575	-
Consulting fees and rent paid to companies controlled by the former CFO	-	9,975
Share-based compensation	360,090	-
<b>Total</b>	<b>\$ 395,565</b>	<b>\$ 60,825</b>

As at March 31, 2021, there was \$270,100 (December 31, 2020 - \$273,850) due to current and former officers and management of the Company.

On January 17, 2020, the Company entered into a loan agreement in the amount of \$50,000 with a company jointly controlled by the former corporate secretary and CFO. The loan was due on demand and interest accrued on the principal amount at the rate of 8% per annum. On April 9, 2020, the loan was settled with common shares of the Company.

**10. FINANCIAL INSTRUMENTS AND RISK MANAGEMENT**

**Financial instruments**

The Company's financial instruments consist of cash and cash equivalents, loans receivable, investments, accounts payable and accrued liabilities and contingent consideration liability. The carrying value of loans receivable and accounts payable and accrued liabilities approximates their fair value due to the short-term nature. Cash and cash equivalents and contingent consideration liability are recorded at fair value using Level 1 of the fair value hierarchy. As at March 31, 2021, investments in public companies of \$372,018 (December 31, 2020 - \$223,670) are recorded at fair value using Level 1 of the fair value hierarchy and investments in private companies of \$11,666,669 (December 31, 2020 - \$166,669) are recorded at fair value using level 2 of the fair value hierarchy.

The Company's financial instruments recorded at fair value require disclosure about how the fair value was determined based on significant levels of inputs described in the following hierarchy:

- Level 1 - Quoted prices are available in active markets for identical assets or liabilities as of the reporting date. Active markets are those in which transactions occur in sufficient frequency and value to provide pricing information on an ongoing basis.
- Level 2 - Pricing inputs are other than quoted prices in active markets included in Level 1. Prices in Level 2 are either directly or indirectly observable as of the reporting date. Level 2 valuations are based on inputs including quoted forward prices for commodities, time value and volatility factors, which can be substantially observed or corroborated in the market place.
- Level 3 - Valuations in this level are those with inputs for the asset or liability that are not based on observable market data.

**GLOBAL CARE CAPITAL INC. (FORMERLY RESINCO CAPITAL PARTNERS INC.)**  
**NOTES TO THE CONDENSED INTERIM FINANCIAL STATEMENTS**  
**FOR THE THREE MONTH PERIOD ENDED MARCH 31, 2021 AND 2020**  
**(UNAUDITED - EXPRESSED IN CANADIAN DOLLARS)**

**10. FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (continued)**

**Financial Instruments (continued)**

The following table presents the Company's financial instruments, measured at fair value on a recurring basis on the statements of financial position and categorized into levels of the fair value hierarchy:

	Level 1	Level 2	Level 3	Total
March 31, 2021	\$	\$	\$	\$
Cash and cash equivalents	505,187	-	-	505,187
Investments	372,018	11,666,669	-	12,038,687

  

	Level 1	Level 2	Level 3	Total
December 31, 2020	\$	\$	\$	\$
Cash and cash equivalents	321,608	-	-	321,608
Investments	223,670	166,669	-	390,339
Contingent consideration liability	-	-	1,700,000	1,700,000

There were no transfers between levels during the period.

The following table reconciles the Company's Level 3 fair value investments:

Level 3	Period ended March 31, 2021	Year ended December 31, 2020
	\$	\$
Balance, beginning	-	462,001
Additions	-	40,641,687
Net change in unrealized gain (loss) on investments	-	(41,103,688)
Balance, ending	-	-

**Risk management**

The Company is or may be subject to certain risks including interest rate risk, currency risk, credit risk and market risk. Risk management strategies may expose the Company to further gains or losses, but serve to stabilize future cash flows, reduce the volatility of operating results and increase overall financial strength.

*Currency risk*

The Company has foreign investments and is therefore subject to currency risk. Management believes these investment and transaction amounts are not significant and there are no material foreign currency commitments. The currency risk is therefore manageable and not significant. The Company does not currently use any derivative instruments to reduce its exposure to fluctuations in foreign currency exchange rates.



**GLOBAL CARE CAPITAL INC. (FORMERLY RESINCO CAPITAL PARTNERS INC.)**  
**NOTES TO THE CONDENSED INTERIM FINANCIAL STATEMENTS**  
**FOR THE THREE MONTH PERIOD ENDED MARCH 31, 2021 AND 2020**  
**(UNAUDITED - EXPRESSED IN CANADIAN DOLLARS)**

---

**10. FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (continued)**

---

**Risk management (continued)**

*Credit risk*

Credit risk is the risk associated with the inability of a third party to fulfil its payment obligations. The Company is exposed to the risk that third parties that owe money or securities in connection with services provided, or for other purposes, will default on their underlying obligations.

Prior to accepting any service engagement or providing any loan, the Company assesses future recoverability by examining the entities' financial conditions, properties and assets, business development activities and management. The Company manages its exposure to credit risk by reviewing the outstanding balances on an ongoing basis, monitoring the amount attributable to each counterparty and the length of time taken for amounts to be settled. Where necessary, management takes appropriate action to follow up on those balances considered overdue.

*Liquidity risk*

Liquidity risk is the risk that the Company will have insufficient cash resources to meet its financial obligations as they become due. The Company's liquidity and operating results may be adversely affected if the Company does not have access to the capital markets, whether as a result of a downturn in general market conditions or related to matters specific to the Company, or if the value of the Company's investments decline, resulting in lower proceeds and/or losses on disposition. The Company generates cash flows primarily from the disposition of its investments and from its financing activities.

The Company's investments focus on early-stage companies which can at times be relatively illiquid and if the Company decides to dispose of certain securities, it may not be able to do so at favorable prices at that time, or at all. However, the Company has sufficient marketable securities which are freely tradable and relatively liquid to fund its obligations as they become due under normal operating conditions such that, in the absence of overall market disruptions or exceptional circumstances, liquidity risk can be minimized.

The Company expects accounts payable and accrued liabilities and contingent consideration liabilities to be settled within 12 months of March 31, 2021.

*Market risk*

Market risk is the risk that the fair value of, or future cash flows from, the Company's financial instruments will significantly fluctuate due to changes in market prices. The value of the financial instruments can be affected by changes in interest rates, foreign exchange rates and equity and commodity prices. The Company is exposed to market risk in trading its investments and unfavourable market conditions could result in dispositions of investments at less than favourable prices. The Company's investments are primarily concentrated in early-stage companies, which results in exposure to higher volatility than broader market investments and indexes. The Company's investments are accounted for at fair value and are sensitive to changes in market bid prices, such that changes in market prices result in a proportionate change in the carrying value of the Company's investments. A 10% change in the fair values of the Company's investments at March 31, 2021 would have a \$1,203,867 (2020 - \$48,000) impact on operations.

**GLOBAL CARE CAPITAL INC. (FORMERLY RESINCO CAPITAL PARTNERS INC.)**  
**NOTES TO THE CONDENSED INTERIM FINANCIAL STATEMENTS**  
**FOR THE THREE MONTH PERIOD ENDED MARCH 31, 2021 AND 2020**  
**(UNAUDITED - EXPRESSED IN CANADIAN DOLLARS)**

---

**10. FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (continued)**

---

**Risk management (continued)**

*Concentration risk*

The Company is subject to concentration risk due to the nature of the Company's operations as an investment company and the number of investments held in the portfolio which consists primarily of early stage companies and their related technologies. As a result, the investment portfolio is directly exposed to the risks associated with companies operating in these industry sectors.

As at March 31, 2021, approximately 99.6% (December 31, 2020 - 82%) of the fair value of the Company's investment portfolio consisted of investments in three (December 31, 2020 – two) companies with the largest single investment comprising 95% (December 31, 2020 - 43%) of the total portfolio value.

**11. MANAGEMENT OF CAPITAL**

---

The Company considers its common shares and options to comprise its capital.

The Company's objectives when managing capital are:

- (a) To ensure that the Company maintains the level of capital necessary to meet its operational requirements;
- (b) To allow the Company to respond to changes in economic and/or marketplace conditions by maintaining its ability to purchase new investments;
- (c) To create sustained growth in shareholder value by increasing shareholders' equity and minimizing shareholder dilution; and
- (d) To maintain a flexible capital structure that optimizes the cost of capital at acceptable levels of risk.

The Company manages its capital structure and makes adjustments to it in the light of changes in economic conditions and the risk characteristics of its underlying assets. The Company maintains or adjusts its capital level to meet its objectives, in order of preference, by:

- (a) Realizing proceeds from the disposition of investments and provision of corporate services; and
- (b) Raising funds through equity financings.

The Company is not subject to any externally imposed capital requirements. Management monitors the Company's capital to ensure capital resources will be sufficient to discharge its liabilities on an ongoing basis.

**12. SUBSEQUENT EVENTS**

---

On April 21, 2021, the Company entered into a share exchange agreement to acquire all of the issued and outstanding common shares and warrants of 1290369 B.C. Ltd. (d/b/a CCM Technologies Inc.) ("CCM"). The Company shall issue from treasury to the shareholders and warrant holders of CCM pro rata 94,170,001 common shares and 65,000,000 common share purchase warrants, respectively. Each warrant provides the holder with an option to purchase one common share of the Company at a price of \$0.05 and 50,000,000 warrants expire on March 1, 2023 and 15,000,000 warrants expire on April 23, 2021. Closing of the transaction is subject to closing conditions including the receipt of all necessary regulatory, stock exchange and shareholder approvals. There can be no assurance that the Transaction will be completed as proposed, or at all.